각막 반흔 시장 : 1차 조사(KOL의 인사이트) - 시장 인텔리전스 - 역학 및 시장 예측(-2034년)

The Corneal Scarring market is hugely contributed using topical corticosteroids and local application of mitomycin C. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the Corneal Scarring therapeutics market. The sales of the emerging therapies for the treatment Corneal Scarring in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2034 study period, adding a value estimated at a total market of $5.7 Billion by 2034.

"Depending on the depth of the scar, different surgical procedures are recommended to remove the scar. In the outer layers of the cornea, the scar may be able to be peeled or scraped away. A scar in the middle layer may be able to be removed in a laser procedure known as PTK (Photo Therapeutic Keratectomy). Corneal transplants, either full or partial, can also be performed to remove the section of the cornea containing the scar."

Corneal Scarring, also known as corneal leukoma or corneal opacity, is a significant concern due to its impact on the transparency and visual function of the cornea. The cornea's highly organized and transparent structure is crucial for its function in transmitting light onto the retina, and any disruption to this architecture can lead to scar tissue formation, impairing vision.

Scarring in the cornea is often the result of fibrotic cellular responses, which, while aiming to heal the tissue, fail to restore its transparency. This is a major concern in corneal diseases and injuries, as scarring can lead to permanent vision loss. The impact of scar tissue formation in the cornea is particularly significant compared to other tissue types, as it directly affects vision.

Mellalta's Corneal Scarring Report- Market Summary

Market Size 2034: $5.7 billion

CAGR%: 3.60%

Key Market Players: Claris Biotherapeutics

Forecast Period: 2020-2034

Countries Covered: US, France, Germany, Italy, Spain, UK, China, and Japan.

Current SOC: Topical corticosteroids; Local application of mitomycin C;

Future SOC: Hepatocyte Growth Factor (HGF)

Key Unmet Need: Standardized Treatment Guidelines; Lack of Approved Pharmaceutical Interventions; Demand for Safer and More Efficacious Treatment Options

Key Insights: Given their affordability and accessibility, current SOC therapies remain viable options for a significant portion of patients.

Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options

Mellalta's Corneal Scarring Report - Epidemiology

The total prevalent cases of Corneal Scarring in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). This increase translates to a CAGR of approximately 0.6% over the 15-year forecast period, underscoring a steady escalation in the incidence of Corneal Scarring. As per estimates, the United States will present with the highest prevalence of Corneal Scarring cases in 2034. Among the EU5, Germany had the highest Corneal Scarring cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States.

Mellalta's Corneal Scarring Report - Current Market Size & Forecast Trends

The Corneal Scarring therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034) to USD 5.7 billion. The United States captured the highest market share as compared to the European 5 countries and Japan.

The current standard of care is limited to therapies such as prednisone acetate ophthalmic suspension, a topical corticosteroid, which is well-established for minimizing corneal scarring, leveraging its anti-inflammatory and antifibrotic properties. Corticosteroids have shown efficacy in reducing TGFb expression, which is considered a key mechanism for antifibrotic therapy in the cornea. MMC, on the other hand, is a potent mitotic inhibitor known for its chemotherapeutic applications. It works by covalently binding with DNA to inhibit synthesis processes, and as an eyedrop, it helps induce apoptosis in myofibroblasts and prevents keratocyte differentiation, playing a crucial role in the management of corneal scarring.

The complexity of treatment regimens, often involving polypharmacy with frequent dosing schedules, exacerbates compliance challenges, particularly among the working-age population where daily responsibilities may impede strict adherence. The introduction of multi agent medications could potentially streamline treatment processes, thereby improving compliance rates. Additionally, the scarcity of accessible written information on ocular chemical burns represents an informational gap that, if filled, could significantly aid in patient and caregiver understanding of the condition and its treatment. Leveraging educational resources and engaging patients' support networks are critical steps toward bolstering treatment adherence.

In the 2024-2034 forecast period, there will be tremendous growth and shift in therapeutic market with the launch of novel emerging therapies like CSB-001 (Claris Biotherapeutics) and others. The emerging therapies will likely replace existing treatments, reflecting a dynamic shift towards more advanced therapeutic options in the Corneal Scarring space and more.

Questions Answered

What is the size of clinically and commercially relevant drug-treatable Corneal Scarring populations, and how will drug-treatment rates change over time?

Potential challenges and opportunities in implementing approved therapy for Corneal Scarring.

What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?

What key drivers and constraints will affect the Corneal Scarring therapy market over the forecast period?

Report Highlights

Corneal Scarring - Current Market Trends

Corneal Scarring - Current & Forecasted Cases across the G7 Countries

Corneal Scarring - Market Opportunities and Sales Potential for Agents

Corneal Scarring - Patient-based Market Forecast to 2034

Corneal Scarring - Untapped Business Opportunities

Corneal Scarring - Product Positioning Vis-a-vis Competitors' Products

Corneal Scarring - KOLs Insight

Table of Content

1.Executive Summary

• 1.1.Key Findings
• 1.2.Key Market Challenges and Opportunities
• 1.3.What Do the Experts Say?

2.Corneal Scarring Disease Background

• 2.1.Corneal Scarring Introduction
• 2.2.Grading of Corneal Opacities
• 2.3.Sign and Symptoms of Corneal Scarring
• 2.4.Causes and Risk factors of Corneal Scarring
• 2.5.Pathogenesis of Corneal Scarring

3.Corneal Scarring Diagnosis

• 3.1.Diagnosis of Corneal Scarring

4.Epidemiology and Patient Populations

• 4.1.Key Findings
• 4.2.Methods and data Sources
  • 4.2.1.Country Specific Diagnosed Prevalent cases of Corneal Scarring
  • 4.2.2.Country Specific Treated cases of Corneal Scarring
• 4.3.Key Sources for Corneal Scarring Epidemiology and Model Parameters
  • 4.3.1.United States
    • 4.3.1.1.United States Diagnosed Prevalent cases of Corneal Scarring
    • 4.3.1.2.United States Treated cases of Corneal Scarring
  • 4.3.2.Germany
    • 4.3.2.1.Germany Diagnosed Prevalent cases of Corneal Scarring
    • 4.3.2.2.Germany Treated cases of Corneal Scarring
  • 4.3.3.France
    • 4.3.3.1.France Diagnosed Prevalent cases of Corneal Scarring
    • 4.3.3.2.France Treated cases of Corneal Scarring
  • 4.3.4.Italy
    • 4.3.4.1.Italy Diagnosed Prevalent cases of Corneal Scarring
    • 4.3.4.2.Italy Treated cases of Corneal Scarring
  • 4.3.5.Spain
    • 4.3.5.1.Spain Diagnosed Prevalent cases of Corneal Scarring
    • 4.3.5.2.Spain Treated cases of Corneal Scarring
  • 4.3.6.United Kingdom
    • 4.3.6.1.United Kingdom Diagnosed Prevalent cases of Corneal Scarring
    • 4.3.6.2.United Kingdom Treated cases of Corneal Scarring
  • 4.3.7.Japan
    • 4.3.7.1.Japan Diagnosed Prevalent cases of Corneal Scarring
    • 4.3.7.2.Japan Treated cases of Corneal Scarring

5.Current Therapies and Medical Practice

• 5.1.Treatment and Medical Practices of Corneal Scarring
• 5.2.Current clinical drug approaches to Corneal Scarring
• 5.3.Current surgical approaches to Corneal Scarring
• 5.4.Common types of corneal transplantations

6.Patient Journey in Corneal Scarring

• 6.1.Referral Routes
• 6.2.Diagnosis Evaluation
• 6.3.Treatment Evaluation
• 6.4.Treatment Choice

7.Unmet Needs in US, EU4, UK, and JP

8.Emerging Therapies

• 8.1.Key Findings
• 8.2.Pipeline Overview
• 8.3.Notable Developments in the Corneal Scarring space
  • 8.3.1.Product Analysis
    • 8.3.1.1.CSB-001 (Claris Biotherapeutics)
      • 8.3.1.1.1.Product Profile
      • 8.3.1.1.2.Clinical Development
      • 8.3.1.1.3.Market & Sales Opportunity Forecasted to 2034
    • 8.3.1.2.Not Exhaustive list (more drugs are covered..)

9.Future Treatment Paradigm

• 9.1.Corneal Scarring Competitor Landscape and Approvals Anticipated
• 9.2.Future Treatment Algorithms and Competitor Positioning
• 9.3.Key Data Summary for Emerging Treatment

10.Annual Cost of Current & Emerging Treatment

11.Late Phase Therapies Strategic Considerations in Corneal Scarring

12.Market Outlook

• 12.1.Key Findings
• 12.2.Overview
• 12.3.Country Specific Market Forecast to 2034
  • 12.3.1.Country Specific Market for Corneal Scarring 2019-2034 (USD Million)
  • 12.3.2.Country Specific Market for Corneal Scarring by Therapies 2019-2034 (USD Million)

13.Market Forecast by Country

• 13.1.United States
  • 13.1.1.United States Market for Corneal Scarring 2019-2034 (USD Million)
  • 13.1.2.United States Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
• 13.2.Germany
  • 13.2.1.Germany Market for Corneal Scarring 2019-2034 (USD Million)
  • 13.2.2.Germany Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
• 13.3.France
  • 13.3.1.France Market for Corneal Scarring 2019-2034 (USD Million)
  • 13.3.2.France Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
• 13.4.Italy
  • 13.4.1.Italy Market for Corneal Scarring 2019-2034 (USD Million)
  • 13.4.2.Italy Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
• 13.5.Spain
  • 13.5.1.Spain Market for Corneal Scarring 2019-2034 (USD Million)
  • 13.5.2.Spain Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
• 13.6.United Kingdom
  • 13.6.1.United Kingdom Market for Corneal Scarring 2019-2034 (USD Million)
  • 13.6.2.United Kingdom Market for Corneal Scarring by Therapies 2019-2034 (USD Million)
• 13.7.Japan
  • 13.7.1.Japan Market for Corneal Scarring 2019-2034 (USD Million)
  • 13.7.2.Japan Market for Corneal Scarring by Therapies 2019-2034 (USD Million)

14.Market Drivers and Constraints

• 14.1.1.What Factors Are Driving the Market for Corneal Scarring?
• 14.1.2.What Factors Are Constraining the Market for Corneal Scarring?

15.Appendix

• 15.1.Methodology